Key facts
- Voyager Biomedical’s last known valuation is $13.0M (Apr 2025).
- It has raised $5.8M across 2 recorded rounds; the latest was Early Stage VC ($5.8M) in Mar 2025.
- Notable investors include MedTech Innovator, National Institutes of Health, Texas Medical Center, Houston Angel Network.
- Voyager Biomedical has filed 2 Form Ds with the SEC since 2020, most recently Apr 2025 ($5.8M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Voyager Biomedical
Funding rounds
2 roundsAbout Voyager Biomedical
Developer of a cannulation device designed to improve the lives of dialysis patients through the development of novel vascular access. The company's device helps to assist with locating veins while preventing excess needle punctures and ensuring that the needle is on target every time, enabling medical professionals to stop deep needle infiltration that can cause infection, blood loss through the back wall of the vein, and fistula damage.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2016
- Employees
- 10
- Website
- voyagerbiomedical.com/
- Ownership
- Privately Held (backing)
Voyager Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Voyager Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Voyager Biomedical in its N-PORT filings yet. We sweep new filings monthly.